Analysis of the diagnostic value of microRNA⁃21/PARP⁃1 as biomarkers in AR and CARAS
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
文章评论
摘要:
目的：评估外周血microRNA（miR）-21、血浆聚腺苷二磷酸核糖聚合酶1[poly（ADP-ribose）polymerase-1，PARP-1] 在过敏性鼻炎（allergic rhinitis，AR）和过敏性鼻炎-哮喘综合征（combined allergic rhinitis and asthma syndrome，CARAS）中的诊断价值。方法：收集44例CARAS患者、31例AR患者和42例健康对照的外周血，采用RT-qPCR法检测外周血中miR-21的表达水平，采用ELISA法检测血浆中PARP-1蛋白水平。应用Pearson进行相关性分析。受试者工作特征（receiver operating characteris- tic，ROC）曲线判断miR-21和PARP-1的诊断灵敏度与特异度。结果：CARAS 组患者外周血miR-21的表达较健康对照组升高。AR组患者血浆 PARP-1的水平较CARAS组和健康对照组升高。Pearson相关性分析结果显示，外周血miR-21的表达水平在AR患者中与嗜酸性粒细胞计数相关，在CARAS患者中与鼻呼出气一氧化氮（fractional nasal nitric oxide，FnNO）水平相关；血浆 PARP-1在AR患者中与1秒钟用力呼气量占预计值百分比（forced expiratory volume in one second percent predicted，FEV1%pred）相关，在CARAS患者中与FEV1%pred及1秒钟用力呼气量（forced expiratory volume in one second，FEV1）/用力肺活量（forced vital capacity，FVC）（FEV1/FVC）相关。ROC曲线分析显示，外周血miR-21 作为 CARAS 的诊断标志物时，灵敏度为 51.35%，特异度为 80.95%。血浆 PARP-1 作为 AR 的诊断标志物时，灵敏度为 90.32%，特异度为 54.76%。血浆PARP-1作为AR进展为 CARAS的诊断标志物时，灵敏度为 45.45%，特异度为 90.32%。结论：AR和CARAS患者外周血miR-21、PARP-1存在差异表达，外周血miR-21可作为CARAS的诊断标志物，PARP-1可作为AR的诊断标志物及AR进展为CARAS的生物标志物。这对寻求AR和CARAS的诊治靶点有十分重要的价值。
Abstract:
Objective：To evaluate the diagnostic value of peripheral blood microRNA（miR）-21 and plasma poly（ADP - ribose） polymerase-1（PARP-1）in allergic rhinitis（AR）and combined allergic rhinitis and asthma syndrome（CARAS）. Methods：Peripheral blood samples were collected from 44 CARAS patients，31 AR patients，and 42 healthy controls. The expression levels of miR-21 in peripheral blood were detected by RT-qPCR，and the plasma levels of PARP-1 protein were measured by ELISA. Correlation analysis was performed by rearson correlation analysis. The diagnostic sensitivity and specificity of miR- 21 and PARP-1 were determined by receiver operating characteristic（ROC）curve. Results：The expression of peripheral blood miR - 21 was high in CARAS patients compared with healthy controls. The level of PARP - 1 was higher in AR patients than that in CARAS patients and healthy controls. Pearson correlation analysis showed that the expiression of miR - 21 was correlated with eosinophils count in AR patients and with fractional nasal nitric oxide（FnNO）in CARAS patients. The plasma level of PARP-1 was correlated with forced expiratory volume in one second percent predicted（FEV1%pred）in CARAS patients and with FEV1%pred and forced expiratory volume in one second（FEV1）/forced vital capacity（FVC）（FEV1/FVC）in CARAS patients. ROC curve analysis showed that when peripheral blood miR-21 was used as a diagnostic marker for CARAS，the sensitivity was 51.35% and the specificity was 80.95%. When the plasma PARP -1 was used as a diagnostic marker for AR，the sensitivity was 90.32% and the specificity was 54.76%. When the plasma PARP-1 was used as a diagnostic marker for the progression from AR to CARAS，the sensitivity was 45.45% and the specificity was 90.32% . Conclusion：There are differential expressions of miR -21 and PARP -1 in peripheral blood of patients with AR and CARAS. the peripheral bolld miR -21 can serve as a diagnostic biomarker for CARAS，while the plasma PARP-1 can serve as a diagnostic biomarker for AR and as a biomarker for the progression from AR to CARAS. This has significant value in identifying diagnostic and therapeutic targets for AR and CARAS.
